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Chemokines are part of the larger cytokine family and induce
cellular migration in cells expressing the appropriate chemo-
kine receptors. Chemokines and their receptors have also
been recognized as important mediators of cell-cell signaling
in both the periphery (Rossi and Zlotnik 2000; Mackay 2001;
Moser et al. 2004; Rot and von Andrian 2004) and in the
central nervous system (for review see Bacon and Harrison
2000; Bajetto et al. 2002; Biber et al. 2002; Ambrosini and
Aloisi 2004). Moreover, the induction of chemokine expres-
sion in the CNS has been associated with various neuronal
insults and neurodegenerative diseases such as ischemia,
epilepsy, Alzheimer’s disease, Amyotrophic Lateral Sclero-
sis, Multiple Sclerosis, and human immunodeﬁciency virus-
encephalitis (for review see Cartier et al. 2004). Although
microglia and astrocytes are the principal source of chemo-
kines in the CNS, recent ﬁndings have shown that neurons
express and secrete chemokines as well (for review, see de
Haas et al. 2007), suggesting that chemokines and their
receptors play a role in local neuro-glial signaling (Hessel-
gesser and Horuk 1999; Ambrosini and Aloisi 2004; Biber
et al. 2007).
Recently, we have shown that chemokine CCL21 is up-
regulated in neurons in vivo and in vitro after injury. As
CCL21 activates microglia through the chemokine receptor
CXCR3, a role of CCL21-CXCR3 in neuron-microglia
signaling has been proposed (Biber et al. 2001; Rappert
et al. 2002; de Jong et al. 2005). CCL21 is not the only
neuronal chemokine that binds and activates CXCR3 as
CXCL10, a major CXCR3 ligand is found in neurons as well
(Wang et al. 1998; Rappert et al. 2004; Klein et al. 2005). In
order to investigate whether CXCL10 might also serve as a
signal between endangered neurons and microglia, we have
here examined the expression and regulation of CXCL10 in
cultured neurons in more detail.
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Abstract
Chemokines expressed in neurons are important mediators
in neuron-neuron and neuron-glia signaling. One of these
chemokines is CCL21 that activates microglia via the
chemokine receptor CXCR3. As neurons also express
CXCL10, a main ligand for CXCR3, we have thus investi-
gated in detail the expression pattern of CXCL10 in neurons.
We show that CXCL10 is constitutively expressed by neu-
rons, is stored in large dense-core vesicles and is not
regulated by neuronal injury or stress. Neuronal CXCL10
release occurred constitutively at low level. In vivo CXCL10
expression was found in the developing brain at various
embryonic stages and its peak expression correlates with the
presence of CD11b- and GFAP-positive cells expressing
CXCR3. These results suggest a possible role of neuronal
CXCL10 in recruitment and homing of glial cells during
embryogenesis.
Keywords: chemokines, CXCL10, microglia, neuronal injury,
neurons, vesicles.
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Materials and methods
Chemicals
Culture media and supplements were all obtained from GIBCO
(Invitrogen, Breda, The Netherlands), unless mentioned otherwise.
The amyloid-beta peptide 1–42 (Ab1-42) used in this study was
kindly provided by Prof. Dr. B. Penke from the Department of
Medical Chemistry, University of Szeged, Hungary.
Cell cultures
Cortical neurons
Cultures of cortical neurons were prepared as described before
(Biber et al. 2001). In brief, cortices from embryonic day 16
embryos were dissected in ice-cold Hank’s balanced salt solution
(HBSS) supplemented with 30% glucose and were placed in a
0.25% trypsin solution at 37C for 20 min. Subsequently, tissue was
gently dissociated by trituration and then ﬁltered through a 70 lm
Falcon cell strainer (BD Biosciences, Erembodegem, Belgium).
After one washing step (100 g for 10 min), cells were resuspended
in complete neurobasal medium (2% B27-supplement, 0.5 mM
glutamine, 1% pen/strept), seeded on poly-D-lysine (Sigma-Aldrich
Chemie BV, Zwijndrecht, The Netherlands)-coated glass coverslips
and maintained at 37C in a humidiﬁed atmosphere with 5% CO2.
Mixed neuronal-glial co-cultures
Mouse cortex from newborn mouse pups (1–3 days old) were
dissected in medium A (HBSS with 0.585% Glucose, 15 mM
HEPES buffer and 1% pen/strept). Cortices were chopped and
places in a 0.25% trypsin solution at 37C for 20 min. The
cortices were triturated with ﬁre polished glass pipettes. Before
centrifugation, 25 mL of culture medium [Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with 4.5 g/L glucose, 2 mM L-
glutamine, 1% pen/strep and 1% sodium pyruvate] was added.
Cells were centrifuged (143 g for 10 min) and resuspended in
complete Neurobasal medium and seeded in culture ﬂask
(75 cm2). Cultures were maintained at 37C, in a humidiﬁed
atmosphere (5% CO2).
Neuroblastoma-glioma 108 cells
Neuroblastoma-glioma 108 (NG-108) cells were cultured in DMEM
containing 10% Fetal Calf Serum (FCS), 1% pen/strept and 1%
sodium pyruvate. Neuronal-like differentiation of NG-108 cells was
done by transferring to differentiation medium (DMEM with 0.5%
FCS, 1% pen/strept, 1% sodium pyruvate, 10 lM 5-N-ethylcarbox-
amide adenosine (Sigma), and 1 lM 3-isobutyl-1-methylxantine
(Sigma).
Plasmids
The following primers have been used to amplify Neuropeptide Y-
enhanced green ﬂuorescent protein (NPY-EGFP) and Vesicle-
associated membrane protein 2 (VAMP2)-EGFP for subcloning




GAAGTAAACGATGATG. CXCL10-pHluorin was subcloned into
XhoI-EcoRI sites of pHluorin-N3 using the following primers:
CXCL10F 5¢-ATACTCGAGATGAACCCAAGTGCTGCCGTCAT-
TTTC; CXCL10B 5¢-ATAGAATTCAAAGGAGCCCTTTTAGAC-
CTTTTTTGGCTAAA. pCXCL10-mRFP was kindly provided by
Dr. R. Miller (Northwestern University, Chicago, USA) and
pHluorin-N3 was kindly provided by Dr. R. Toonen (VUMC,
Amsterdam, The Netherlands).
Transfection
Plasmids were transfected into differentiated NG-108 cells using
transfection lipid nanofectamin (PAA Laboratories, Co¨lbe, Ger-
many) according to the manufacturer’s instructions. NG-108 cells
were transfected in DMEM for 5 h and transferred back to
differentiation medium.
Neuronal insults
Excitotoxicity was induced by adding glutamate (100 lM) for
30 min to primary neurons medium as described previously
(Biber et al. 2001) and mRNA/protein samples were taken 0, 2,
4, 6, 12 and 24 h after treatment. Cellular hypoxia was induced
by treating 7 days in vitro primary neurons with 10 mM sodium
azide (Sigma) for 5 min as described elsewhere (Grammatopoulos
et al. 2004). The expression of CXCL10 mRNA and protein was
evaluated 24 h after treatment. Beta-amyloid neurotoxicity was
induced by incubating primary neurons with Ab1-42 oligomers,
which were prepared as followed: the solid Ab1-42 peptide was
dissolved in 1,1,1,3,3,3-hexaﬂuoro-2-propanol (Sigma) at 1 mM
and 1,1,1,3,3,3-hexaﬂuoro-2-propanol was removed by evapora-
tion in a SpeedVac (Savant Instruments, Holbrook, NY, USA).
The Ab1-42 ﬁlms were dissolved in anhydrous dimethylsulfoxide
(Sigma) at 5 mM and subsequently diluted in phenolred-free
neurobasal medium to 100 lM (stock solution). The stock
solution was incubated at 4C for 24 h to enable Ab1-42
oligomers formation. Primary neurons were incubated for 24 h
with 50 lM of Ab1-42 oligomers or phenolred-free neurobasal
media as control. After the incubation with Ab1-42 oligomers, the
cell viability was determined and media samples were collected
and snap frozen in liquid nitrogen for further analyses. To check
if appropriate Ab1-42 oligomers had formed, media were checked
on western blot using the primary anti-Ab antibody 6E10 (Signet
Laboratories, Dedham, MA, USA). The last neurotoxic treatment
applied was heat shock. Brieﬂy, plates containing neurons were
sealed with parafﬁn and were incubated in a waterbath at 42C
for 30 min. Neurons were then put back in the incubator and
samples were taken after 24 h. Plates containing control neurons
were only sealed with parafﬁn for 30 min.
Real-time PCR analysis of CXCL10 mRNA in cultured neurons
Cell lysis, RNA extraction and cDNA transcription were performed
as described previously (Biber et al. 2001). The following primers
for CXCL10 and hydroxymethylbilane synthase (HMBS) were
designed using Primer Designer version 3.0: CXCL10F 5¢-GC-
TGCAACTGCATCCATATCG-3¢; CXCL10B 5¢-CCGGATTCA-
GACATCTCTGCT-3¢ HMBSF 5¢-CCGAGCCAAGGACCAGGAT-
A-3¢; HMBSB 5¢-CTCCTTCCAGGTGCCTCAGA-3¢. HMBS was
used as normalizing gene because its expression remained stable
under various experimental conditions. Experiments were conducted
with an i-cycler (Bio-Rad Laboratories, Hercules, CA, USA) using
96 wells plates containing 25 lL iQ SYBR Green Supermix (Bio-
Rad) with primers in a concentration of 250 nmol/well. Reaction
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conditions were 3 min at 95C, followed by 50 cycles of 10 s at
95C and 45 s at 58C, followed by 1 min at 95C and by 1 min at
55C. Results were normalized to HMBS and the comparative cycle
threshold Ct method was used as described previously (Livak and
Schmittgen 2001).
Immunoprecipitation
Immunoprecipitation for CXCL10 was performed by adding 400 ng
of rabbit anti-murine CXCL10 antibody (PeproTech, London, UK)
to 1 mL supernatant of cultured neurons, NG-108 or HEK293 cells.
Samples were incubated overnight at 4C and Protein G-Sepharose
4 Fast Flow [GE Healthcare, Diegem, Belgium: 50 lL of 50%
slurry in phosphate-buffered saline (PBS)] was added and incubated
for another 4 h. Subsequently, samples were centrifuged at 125 g at
4C and antibody-antigen-Protein G complexes were washed ﬁve
times with PBS. Complexes were dissociated by adding 20 lL 2·
sodium dodecyl sulfate–polyacrylamide gel electrophoresis sample
buffer, heated for 5 min at 95C and subjected to western blotting
(see Fig. S1). As positive control, 80 ng of recombinant CXCL10
was added to 1 mL supernatant of cultured neurons, which was
subjected to the same protocol.
Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde for 30 min, blocked
30 min in PBS containing 0.3% Triton X-100 and 5% normal goat
serum and incubated O/N with rabbit anti-CXCL10 (PeproTech,
1 : 1000) and mouse anti-NeuN (Millipore, Amsterdam Zuidoost,
The Netherlands, 1 : 1000) or mouse anti-Glial ﬁbrillary acidic
protein (GFAP, Millipore, 1 : 200) primary antibodies diluted in
PBS with 0.3% Triton X-100. The next day, cells were incubated
with FITC-goat anti-mouse (Millipore, 1 : 500) and CY3-goat anti-
rabbit (Jackson Immuno-Research, Newmarket, Suffolk, UK,
1 : 500) secondary antibodies for 1 h. Glass coverslips were
mounted on slides with Mowiol (Sigma). Control experiments for
speciﬁcity were done in absence of the primary antibody. NG-108
cells transfected with CXCL10 mRFP were incubated O/N with
rabbit anti-Chromogranin A and B (Novus Biologicals, Littleton,
CO, USA, 1 : 100) and CY3 goat anti-rabbit was used as secondary
antibody.
Mouse embryos were dissected, ﬁxed overnight in 4% formal-
dehyde, embedded in parafﬁn and sectioned at 7 lm thickness.
The sections were deparafﬁnized, hydrated in graded alcohols,
heated for 10 min at 120C, 1 kPa in 10 mM Na-citrate (pH 6.0)
to retrieve antigens, blocked in Teng-T [10 mM Tris (pH 8.0),
5 mM EDTA, 150 mM NaCl, 0.25% (w/v) gelatin, 0.05% (v/v)
Tween-20] and 10% FCS, and incubated overnight with the ﬁrst
antibody. Antibody-antigen reactions were detected using the
biotin-streptavidin method and visualized with 3,3¢-diaminobenzi-
dine (DAB)/H2O2. The slides were rinsed, mounted with DEPEX
and analyzed by light microscopy. Negative control experiments
were performed with isotype-matched antibodies or by omitting
primary antibodies.
Electron microscopy
Electron microscopy immunocytochemistry for the ultrastructural
detection of CXCL10 was performed on cultured cortical neurons
using a biotinylated secondary antibody and the Vectastain ABC
kit (Vector Laboratories, Burlingame, CA, USA) with DAB as
chromogen. Intensiﬁcation of the DAB reaction product was done
using the gold-silver-substituted peroxidase method (Liem et al.
2001). Subsequently, neurons were ﬁxed with 3% sodium
thiosulphate, rinsed brieﬂy in 0.1 M sodium acetate cacodylate
buffer, pH 7.6 and were then osmicated in 1% OsO4 (w/v) and
1.5% potassium hexacyanoferrate in the same buffer. Neurons
were then dehydrated in a graded series of ethanols and embedded
in Epon. One lm sections were cut on a Reichert Ultratome and
stained with toluidine blue to check the presence of relevant areas.
Sixty nm sections were then cut, counter-stained with uranyl
acetate and lead citrate, and examined using a Philips CM100
transmission electron microscope (Aachen, Germany).
Fluorescence-activated cell sorting (FACS) analysis
Brains from embryonic day 14 embryos were dissected in ice-cold
HBSS supplemented with 30% glucose and were placed in a 0.25%
trypsin solution at 37C for 20 min. Subsequently, tissue was gently
dissociated by trituration and then ﬁltered through a 70 lm Falcon
cell strainer. After one washing step (100 g for 10 min), cells were
resuspended in FACS buffer (PBS, supplemented with 0.5% bovine
serum albumin and 0.01% sodium azide). Cells were incubated for
15 min with CD16/32 (eBioscience, Hatﬁeld, UK, 1 : 100) to block
Fc receptor binding. For the membrane-bound proteins CXCR3
(R&D Systems, Abingdon, Oxon, UK, 1 : 10), CD11b (BD
Biosciences, 1 : 200) and isotype controls, ﬂuorescent-conjugated
antibodies were added and cells were incubated for 20 min on ice.
For the detection of intracellular proteins in combination with
membrane-bound markers, cells were ﬁxated after membrane-
antibody staining with freshly prepared 1% paraformaldehyde for
10 min. Subsequently, cells were washed twice with FACS buffer,
supplemented with 0.1% saponin (FACS-SAP) and incubated for
30 min with the either rabbit anti-GFAP (Sigma; 1 : 200) or mouse
anti-Microtubule-associated protein 2 (MAP2, Millipore, 1 : 200)
diluted in FACS-SAP. After thoroughly washing with FACS-SAP,
cells were incubated for 30 min with either goat anti-rabbit
DyLight488 (JacksonImmunoResearch, 1 : 250) or goat anti-mouse
Alexa488 (Invitrogen, 1 : 250), also diluted in FACS-SAP. After
washing, unﬁxed and ﬁxed cells were resuspended in FACS buffer
and ﬂuorescence was measured with a FACS Elite Flow Cytometer
(Becton-Dickinson, Breda, The Netherlands).
ELISA
CXCL10 release in the supernatant of the cells was measured with
an ELISA (R&D). Supernatants were spin down brieﬂy to remove
cells and then used in a mouse-CXCL10 speciﬁc ELISA as
described in the manufacturer’s protocol. Recombinant murine
CXCL10 served as the standard and detection limit was set at 15 pg/
mL.
Fluorescence and timelapse imaging
Imaging of the immunoﬂuorescent staining and the expression of the
various fusion proteins was performed on a Leica AOBS_TCS SP2
confocal laser scanning microscope (Leica Microsystems, Rijswijk,
The Netherlands). CXCL10-pHluorin was visualized in transfected
NG-108 cells using a live-cell imaging set-up (Solamere Technology
Group, Salt Lake City, UT, USA) equipped with an AR/Kr laser
(Dynamic Lasers, Salt Lake City, UT, USA) and a CSU10 spinning
Nipkow disk (Yokogawa, Amersfoort, The Netherlands). Coverslips
 2009 The Authors
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were placed in a motorized xyz stage of a DM IR2 Leica microscope
which was placed in a custom made incubation chamber with an
37C humidiﬁed atmosphere and Tyrode’s solution was used as
buffer. A Stanford Photonics XR MEGA-10 Gen III iCCD camera
(Stanford Photonics, Palo Alto, CA, USA) was used for acquisition.
The setup was controlled by ‘InVivo’ software (Media Cybernetics,
Bethesda, MD, USA). Images were acquired at 1 frame per second
with 330 ms integration time per image using a 63· NA1.4 oil
immersion objective +1.5 Optovar (Leica Microsystems).
Data analysis
Real time PCR results, Western and ELISA data were analyzed by
one-way ANOVA followed by the Bonferroni correction. Values of
p < 0.05 were considered statistically signiﬁcant. FACS data were
analyzed using WinList (Verity Software House, Topsham, ME,
USA) for Windows. Confocal images and acquired time series were
corrected for background noise and were deconvoluted using
Huygens Pro Software (SVI, Hilversum, The Netherlands). Quan-
tiﬁcation of vesicle co-localization was performed using single
channels of red-green confocal images saved separately. Images
were then surimposed together and yellow, green and red puncta
were counted.
Results
Expression of CXCL10 in cultured neurons
In order to study the distribution of CXCL10 in neurons,
we performed ﬂuorescent immunocytochemistry on E16
primary cortical neurons. Control experiments without
primary antibody gave virtually no background staining
(Fig. 1a). Our observations indicate that CXCL10 immu-
noreactivity was found abundantly throughout the whole
cell as punctate signals and that most cells (> 95%) were
positive for CXCL10 (red signal) (Fig. 1b). The majority
(> 95%) of cells in culture that were positive for CXCL10
(red signal) were also NeuN positive (Fig. 1c). Few
CXCL10-positive cells were not positive for NeuN (Fig. 1c,
insert, arrowheads). GFAP immunocytochemistry revealed
that these cells were CXCL10-positive astrocytes (Fig. 1d,
arrowhead).
CXCL10 is stored in large dense-core vesicles
The punctate expression of CXCL10 in neurons (Fig. 1c)
suggests the presence of CXCL10 in vesicle-like structures,
similar to what has been reported for other cytokines/
chemokines (Specht et al. 2003; Mo¨ller et al. 2006; Cal-
lewaere et al. 2008; de Jong et al. 2008; Jung et al. 2008;
Tsakiri et al. 2008). Electron microscopic experiments
conﬁrmed the presence of CXCL10 in vesicle-like structures
at the ultrastructural level. Moreover, CXCL10 was found in
vesicles localized mainly at pre-synaptic sites as indicated for
axo-somatic contacts (Fig. 2a), axo-axonal contacts (Fig. 2b)
and axo-dendritic cell contacts (Fig. 2c).
To further characterize the type of vesicles in which
CXCL10 is stored, we used differentiated NG-108 cells as a
neuron-like cell model in which we transfected CXCL10-
mRFP along with either NPY-EGFP or VAMP2-EGFP,
(a) (b)
(c) (d)
Fig. 1 Distribution pattern of CXCL10 in
neurons. (a) When immunocytochemistry
was performed without primary antibody as
a negative control, no signal could be de-
tected. (b) After the staining procedure, the
majority of cells in the culture were CXCL10
positive. (c) After double-labeling experi-
ment with the neuronal nuclear marker
NeuN (in green), we observed that the
majority of CXCL10 (in red) positive cells
were neurons. However, some CXCL10
positive cells were negative for NeuN
[arrowheads in insert (c)]. (d) These cells
were identified as astrocytes (arrowhead;
GFAP in green, < 5%). Scale bars: (a, b, d)
and insert (c) = 50 lm; (c) = 10 lm. Similar
results have been obtained in at least four
independent experiments.
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which are marker for large dense-core vesicles. 68 ± 5.9% of
the CXCL10-containing vesicles were found to be co-
localized with NPY-EGFP (Fig. 3a). In the case of VAMP2-
EGFP, only a partial co-localization (54 ± 6.6%) with
CXCL10-mRFP was observed (Fig. 3b). We also processed
differentiated NG-108 cells transfected only with CXCL10-
mRFP for immunohistochemistry against Chromogranins A
and B, another large dense-core vesicle marker, and observed
a 34 ± 2.3% co-localization of CXCL10 vesicles with
Chromogranins A and B (Fig. 3c).
(a) (b) (c)
Fig. 2 Ultrastructural localization of
CXCL10 in vesicles. CXCL10 is localized in
vesicles in synaptic areas that make an (a)
axo-somatic contact, (b) axo-axonal contact
and (c) axo-dendritic contact. Arrowheads
indicate CXCL10 immunoreactivity. Scale




Fig. 3 CXCL10 is sorted into large dense-core vesicles. Differentiated
NG-108 cells were co-transfected with pCXCL10-mRFP (a,d) and
pNPY-EGFP (b) or pVAMP2-EGFP (e) and subsequently analyzed for
co-localization (c,f). Differentiated NG-108 cells showed partial overlap
of CXCL10 with NPY [arrowheads in insert (c)] and VAMP2 [arrow-
heads in insert (f)]. Differentiated NG-108 cells transfected with
pCXCL10-mRFP (g) were processed for immunohistochemistry
against chromogranins A + B (h). Analysis of the overlay revealed a
partial overlap of CXCL10 vesicles with chromogranins A + B
[arrowheads in insert (i)]. Scale bars = 10 lm.
 2009 The Authors
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Constitutive CXCL10 expression in cultured neurons is not
changed after neurotoxic stimuli
Using quantitative real-time PCR, CXCL10 mRNA was
detected in cultured neurons under control conditions, which
was not affected by treatment with the NMDA-receptor
antagonist MK801 (50 lM for 24 h) indicating that basal
CXCL10 mRNA expression was not because of excitotoxic
events in the culture (Fig. 4a). No signiﬁcant differences in
CXCL10 mRNA expression levels were observed after
treatment with 100 lM glutamate for 0–24 h. These results
were also conﬁrmed at protein level (Fig. S1). Other
neuronal insults such as treatment with amyloid beta Ab1-
42 oligomers, chemical hypoxia induced with sodium azide
and heat shock did not result in changes of CXCL10 mRNA
expression 24 h after treatment (Fig. 4a). As CXCL10 is
known to be expressed in glial cells, we also determined
CXCL10 mRNA expression levels in mixed glia cell
cultures. Compared to cultured neurons, a signiﬁcant higher
CXCL10 mRNA expression (10-folds increase) was found in
mixed glia cells (Fig. 4b; p < 0.05). The mRNA expression
of CXCL10 in mixed glia cells was furthermore strongly
stimulated by lipopolysacharide (LPS, 100 ng/mL for 6 h)
up to 170-times of control values (Fig. 4b). Twenty four
hours after treatment with LPS, mixed glia cell cultures still
expressed approximately 10-times more CXCL10 mRNA
compared to controls (Fig. 4b).
Release of CXCL10
The vesicular presence of CXCL10 at pre-synaptic sites
prompted us to investigate the release of CXCL10 from
neuronal cultures. ELISA were performed with supernatants
of primary cultured cortical neurons that were exposed to the
various treatment mentioned above. Additionally, two con-
ditions known to induce vesicular release (60 lM KCl for
6 h to induce depolarization and 1 lM ionomycin to induce
calcium inﬂux) were tested. None of these samples contained
CXCL10 at a concentration that was signiﬁcantly above the
detection limit of our ELISA assay (15 pg/mL). This was in
contrast with supernatants obtained from mixed glial
cultures, containing astrocytes and microglia, in which
CXCL10 was detected reliably (332.3 ± 8.1 pg/mL). Partic-
ularly after LPS treatment (100 ng/mL for 24 h), the
concentration of CXCL10 was very high (71 168.0 ±
1341.8 pg/mL; Fig. 5a).
As no detectable amount of CXCL10 was found in the
supernatants, we investigated if the vesicles containing
CXCL10 were fusing with the membrane with the help of
CXCL10-pHluorin. We therefore performed live imaging
experiments in differentiated NG-108 cells that were
transfected with CXCL10-pHluorin. We observed that
CXCL10-ﬁlled vesicles are constitutively fusing with the
membrane. Indeed, we observed vesicles that were already
fused with the membrane at the beginning of the experi-
ments and remained there for several seconds (almost
1 min) (Fig. 5b; left panel; arrows). These fusion events
disappeared over time due probably to reacidiﬁcation of
the vesicles lumen (Fig. 5b; right panel; arrows). After
more than 1 min, new ﬂuorescent events were observed at
the membrane (Fig. 5b; right panel; arrowheads), clearly
indicating that CXCL10-ﬁlled vesicles are fusing with the
cell membrane and suggesting that CXCL10 is indeed
released. However, the number of fusion events was
relatively low and treatment with 100 lm glutamate or
(a)
(b)
Fig. 4 Expression of CXCL10 mRNA in cultured neurons and mixed
glial cultures. (a) Real-time PCR showed no significant difference in
CXCL10 mRNA levels in the neuronal cultures after MK801 treatment
(50 lm for 24 h) or at every time-point after 100 lM glutamate (2–
24 h), sodium azide (Az: 10 mM for 24 h), amyloid beta (ab: 50 lM for
24 h) and heat shock (HS: 42C for 30 min, analyzed after 6 h) when
compared to the control condition. (b) CXCL10 mRNA expression in
cultured neurons (11 ± 8%) was significantly lower than in non-chal-
lenged mixed glia cultures (100 ± 9%). LPS treatment strongly in-
duced CXCL10 mRNA expression in mixed glial cultures after 6 h
(approx. 170-fold increase) and 24 h (approx. 10-fold increase).
Similar results have been obtained in at least three independent
experiments. Data are given as mean ± SEM. *Significantly different
from control values, p < 0.05.
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50 mM KCl did not increase the frequency of release (data
not shown). To conﬁrm that CXCL10 is released from these
vesicles, additional immunoprecipitation experiments were
performed to detect CXCL10 in neuronal supernatants.
Indeed, CXCL10 was found in neuronal supernatants under
control conditions (Fig. 5c). Again, glutamate treatment
(100 lM for 6 and 12 h) did not affect the neuronal release
of CXCL10 (Fig. 5c). CXCL10 was also found in the
supernatant of differentiated NG-108 that express constitu-
tively CXCL10, whereas supernatant of HEK293 cells that
do not express CXCL10 was devoid of any signal (Fig. 5c)
and thus served as negative control. As only faint bands
were detected, the levels of CXCL10 were rather low
thereby corroborating the results gained with ELISA. In
order to investigate whether the low amounts of CXCL10
were because of turnover or binding of CXCL10 in these
cultures, the fate of exogenously applied recombinant
CXCL10 in our system was tested. Cortical neurons were
cultured for 6 h in the presence of 100 pM CXCL10 and
subsequently the levels of CXCL10 in the supernatants
were evaluated. The results showed that the culture
conditions led to a decrease up to 60–70% in the
concentration of exogenously added CXCL10.
CXCL10 is expressed in the developing mouse brain
In order to investigate whether neurons in vivo also express
CXCL10, immunohistochemical studies have been per-
formed. No neuronal CXCL10 was found in the brain of
adult mice or neonatal animals (postnatal day 1–3), nor did
we ﬁnd CXCL10 immunoreactivity in neurons in hippocam-
pal organotypic brain slice cultures (data not shown). In the
developing brain, however, CXCL10 expression was found.
In brain derived from embryonic day 10.5 CXCL10 was
observed at the ventricular side of the developing neuropil
(Fig. 6, arrows). At embryonic day 12.5 the whole develop-
ing brain was positive for CXCL10 (Fig. 6) and at embryonic
day 17.5 CXCL10 expression was restricted to layers of the




Fig. 5 Release of CXCL10 in neuronal cultures is low. (a) Using the
ELISA, no detectable amount of CXCL10 was found in the superna-
tants of cultured neurons after stimulation with 100 lM glutamate (glu:
24 h), sodium azide (Az: 10 mM for 24 h), amyloid beta (ab: 50 lM for
24 h), KCl (60 lM for 6 h), ionomycin (Io: 1 lM for 6 h) and heat shock
(HS: 42C for 30 min, analyzed after 6 h). CXCL10 was readily de-
tected in the supernatants of mixed glial cultures especially after
treatment with 100 ng/mL LPS for 24 h. Data are given as mean ±
SEM (n = 3). (b) Time lapse imaging of differentiated NG-108 cells
transfected with CXCL10-pHluorin showed fluorescent signal at the
beginning of the experiment indicative of vesicles fusing with the
membrane (arrows, left panel). Several seconds later, these vesicles
disappeared (arrows, right panel) and new fluorescent signal ap-
peared elsewhere in the cells (arrowheads, right panel) indicating new
fusion events. (c) Immunoprecipitation experiments revealed the
presence of CXCL10 in supernatants of cultured neurons under con-
trol conditions (c) and after glutamate treatment (6 and 12 h) and of
differentiated NG-108 cells (NG). HEK293 cells served as negative
control (nc). As positive control, 80 ng of recombinant CXCL10 were
added to neuronal supernatant and subjected to immunoprecipitation.
Similar results have been obtained in four independent experiments
for ELISA analysis and three independent experiments for immuno-
precipitation.
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The embryonic period in which neurons are expressing
CXCL10 is characterized by the appearance of myeloid cells
(future microglia) and astrocytes which are colonizing the
CNS and proliferating (Alliot et al. 1999; Sauvageot and
Stiles 2002). In order to identify CXCR3 receptor expressing
cells in the developing brain, FACS analysis of unﬁxed E14
CNS cells were performed. Forward/side scatter analysis
showed two main cell clusters (Fig. 7a), only one of which
(region one) was positive for CXCR3 (Fig. 7b and c). Within
the cells of region one, we detected two populations of
CXCR3-expressing cells: one expressing high levels and one
expressing low levels of CXCR3 (Fig. 7b). As 9% of the
region one cells were CD11b positive (Fig. 7e), double
staining experiments with CD11b and CXCR3 were per-
formed. These experiments identiﬁed CD11b-positive cells
as CXCR3 high expressors (Fig. 7f). In order, to detect if,
next to myeloid cells, also neurons and astrocytes expressed
CXCR3, E14 CNS cells were ﬁxed and double stained with
MAP2/CXCR3 or GFAP/CXCR3. Cell ﬁxation made the
two populations less distinct on the forward/side scatter
(Fig. 7g) but nevertheless CXCR3 was expressed mainly by
cells of region one (Fig. 7h), although some cells of region
two were also positive for CXCR3 (Fig. 7i), probably
because of loss of cell granularity by ﬁxation. Fixation also
made the two CXCR3 population indistinguishable (Fig. 7h).
MAP2-positive cells were found only in region two cells
(Fig. 7j), conﬁrming that neurons do not express CXCR3.
Interestingly, GFAP-positive cells were found in both regions
(Fig. 7k). Double staining experiments with CXCR3 and
GFAP revealed that majority of astrocytes cells found in
region 1 expressed CXCR3 (Fig. 7l). Again, because of
ﬁxation, some astrocytes belonging to region 1 were found in
region 2 and expressed also CXCR3 (Fig. 7l).
Discussion
Neuronal CXCL10 is constitutively expressed in vitro
The present study shows that cultured cortical neurons
constitutively express CXCL10, which is distributed
throughout the whole cell including synaptic regions.
Furthermore, CXCL10 mRNA and protein levels could
not be induced by neuronal insults. Immunohistochemical
studies in brain of mouse embryos detected CXCL10
expression at embryonic day 12.5 and 17.5. No neuronal
CXCL10 expression was found in neonatal brains or
organotypic hippocampal slices cultures derived from 3-
day-old animals.
Fig. 6 Immunohistochemical analysis re-
vealed the expression of CXCL10 in the
developing mouse brain. At embryonic day
10.5, CXCL10 was detected at the ventric-
ular wall of the developing neuropil (ar-
rows). CXCL10 immunoreactivity was more
prominent in the developing brain at
embryonic day 12.5, where CXCL10 could
be observe throughout the nervous tissue.
At embryonic day 17.5, CXCL10 immuno-
reactivity was restricted to layers in the
developing forebrain (arrows). Scale
bar = 500 lm.
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Fig. 7 CD11b and GFAP positive cells from E14 CNS express
CXCR3 receptor. E14 CNS cells were processed for FACS analysis.
(a) Two populations were identified in the forward/side scatter (region
1 and 2). CXCR3-positive cells were found in region 1 (b) but not in
region 2 (c). Isotype control gave no signal (d). Staining with CD11b
antibody showed expression only in region 1 (e). (f) Double labeling
with CD11b and CXCR3 showed that all CD11b-positive cells ex-
pressed high levels of CXCR3, while isotype controls gave no signal.
To identify, whether neurons and astrocytes expressed also CXCR3,
E14 CNS were fixed and processed for FACS analysis. Although less
distinct, the two population were observed on the forward/side scatter
(g) and CXCR3 was present mainly in region 1 (h) but not in region 2
(i). MAP2 staining revealed that neurons are present only in region 2
(k), and thus do not express CXCR3. GFAP-positive cells were ob-
served in both regions (k). Double labeling with GFAP and CXCR3
showed that part of the GFAP-positive cells of region 1 expressed also
CXCR3 (l). Because of fixation, some GFAP-positive cells expressing
CXCR3 were also observed in region 2 (l). Isotype controls gave no
signals (l). FSC, forward scatter; SSC, side scatter.
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In agreement with our results a constitutive expression of
CXCL10 in cultured neurons (human fetal brain cells) has
been described (Sui et al. 2004) whereas others did not ﬁnd
CXCL10 expression in untreated neurons (Patterson et al.
2003; Klein et al. 2005). The reason for these contradictory
ﬁndings is not clear but might reﬂect differences in culture
conditions. The ﬁrst report describing a neuronal CXCL10
expression was by Wang et al. (1998) where they showed an
induction of CXCL10 in neurons under ischemic conditions.
However, they furthermore reported a low level of CXCL10
mRNA expression in sham-operated animals and also at the
contralateral cortical side of treated animals, suggesting a
basal level of neuronal CXCL10 mRNA expression. Thus,
controversial results have been published concerning the
expression of CXCL10 in unchallenged neurons, indicating
that neuronal CXCL10 expression may depend on the
developmental stage.
Release of neuronal CXCL10
CXCL10 was observed in punctuate structures that were
identiﬁed as large dense-core vesicles using speciﬁc markers.
These data are in accordance with other recent ﬁndings on
the localization and release of neuronal cytokines or
chemokines from vesicles (Specht et al. 2003; Mo¨ller et al.
2006; Callewaere et al. 2008; de Jong et al. 2008; Jung et al.
2008; Tsakiri et al. 2008). It further implies that neurons
probably actively transport CXCL10 to various cell com-
partments as we previously demonstrated with CCL21 (de
Jong et al. 2008).
The presence of CXCL10-vesicles in synaptic regions
suggests that CXCL10 might be released from neurons.
From our thorough analysis, we conclude that CXCL10 is
released from cultured neurons, albeit at very low levels.
This was in contrast with supernatants derived from mixed
neuronal/glial cultures. There are three recent studies that
investigated the release of CXCL10 from virus-infected
neurons. Measles infection induced both CXCL10 and
CCL5 in primary hippocampal neurons but interestingly,
only CCL5 release was detectable by ELISA (Patterson
et al. 2003). Using western blot analysis, Klein and
colleagues showed high CXCL10 levels within West Nile
virus infected cerebellar granule neurons but only low
levels in the supernatant of these cells (Klein et al. 2005).
Relatively high levels (around 1000 pg/mL) of CXCL10
were found in the supernatant of simian human immuno-
deﬁciency virus- or gp120-treated human fetal brain
cultures (Sui et al. 2004). It should be noted, however,
that the human fetal brain cultures used in this study
contained approximately 30% astrocytes, whereas all other
studies concerning CXCL10 expression in cultured neurons
(including ours) used almost pure neuronal cultures (Patt-
erson et al. 2003; Klein et al. 2005). It is thus apparent that
CXCL10 in neurons can be reliably detected, whereas the
presence of CXCL10 in neuronal supernatants is more
difﬁcult to show. Moreover, we show that the concentration
of exogenously added CXCL10 into the supernatant of
cultured neurons decreases, furthermore complicating the
detection of CXCL10 in neuronal supernatants. Even
though we show that CXCL10 is present in vesicles in
synaptic areas, suggesting that CXCL10 is destined for
release, we hardly detected its presence in the culture
medium.
The function of neuronal CXCL10
The ﬁndings presented here concerning the expression of
CXCL10 in embryonic cultured neurons and in the devel-
oping mouse brain suggest a function of this chemokine in
brain development. Indeed, we show that myeloid cells
(CD11b-positive) and some GFAP-positive cells express the
receptor CXCR3. Myeloid cells, which will give rise to
resident microglia, are known to colonize the CNS from E7
(Alliot et al. 1999), while astrocytes will start appearing at
E12 (Sauvageot and Stiles 2002). As, this is the period when
neuronal CXCL10 is expressed in the developing brain
(between E12 and E17), a possible role for CXCL10 during
embryogenesis can be envisaged. CXCL10 could function as
a ‘homing’ molecule to attract CXCR3-positive cells. Indeed,
several studies are showing a prominent role of chemokines
in cellular migration also during development (Ragozzino
2002; Rezaie et al. 2002). However, as low amount of
CXCL10 were detected in culture, it is more likely that
CXCL10 provides a local signal. Thus, CXCL10 might be
involved during apoptosis (which occurs abundantly during
development) and cellular clearance from myeloid cells (Rice
and Barone 2000) and/or could promote contact between
glial cells and neurons, which is critical for synaptogenesis in
later stages of development (Ullian et al. 2004). During
embryogenesis, both radial glia and astrocytes express GFAP
(Hartfuss et al. 2001) and the presence of these two cell
types may explain why not all GFAP-positive cells expressed
CXCR3. Moreover, we were not able to identify all the cells
that expressed CXCR3. It is plausible that other cell types
such as precursors cells and/or immature cells might express
the receptor. In order to prove these hypotheses, however,
further studies should be performed.
Earlier ﬁndings of our group suggested that the receptor
for CXCL10, CXCR3, is instrumental in neuron-microglia
signaling (Rappert et al. 2004). We have suggested CCL21
to provide the neuronal signal for this intercellular signal-
ing. The data presented here do not support a function of
CXCL10 in neuron-microglia signaling under excitotoxic
conditions. However, this might be different in case of
virus-infected neurons in which CXCL10 expression is
induced.
In summary, it is shown here that CXCL10 is constitu-
tively expressed in cultured cortical neurons and that its
expression is not changed by endangering conditions. The
function of neuronal CXCL10 is not yet understood,
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however, the data presented here show that neuronal
CXCL10 could play a role during embryogenesis.
Supporting information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Western blot analysis corroborated the presence of
CXCL10 in cultured neurons.
As a service to our authors and readers, this journal provides
supporting information supplied by the authors. Such materials are
peer-reviewed and may be re-organized for online delivery, but are
not copy-edited or typeset. Technical support issues arising from
supporting information (other than missing ﬁles) should be
addressed to the authors.
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